Vitals
- Healthcare added 436,000 jobs in the past 12 months, representing 121% of all United States jobs created from January 2025 to January 20261
- HealthTech mergers and acquisitions (M&A) deal value soared 87% to 31.8 billion euros; private equity (PE) healthcare deals account for 38% of transaction value
- HIMSS 2026 opens in Las Vegas with 25,000 or more healthcare leaders; agentic artificial intelligence (AI) dominates the agenda
- One Big Beautiful Bill Act (OBBBA) Medicaid cuts quantified at $665 billion through 2034 by the RAND Corporation
- Food and Drug Administration (FDA) faces operational crisis as government shutdown halts new drug, biologic, and device submissions
- Massachusetts requires quarterly disclosure of PE healthcare platform investments beginning January 1, 2026
Peaks
Healthcare Remains America's Jobs Engine
Healthcare added 693,000 jobs in 2025. Without healthcare, the US economy would have lost 570,000 jobs. The sector accounted for 95% of the 130,000 jobs added in January 2026, according to the Washington Post. Healthcare is not just outperforming other sectors; it is single-handedly preventing labor market contraction. But the foundation is showing cracks: February 2026 will bring the first job losses in over four years.2
Why it matters: Healthcare's role as the economy's backstop is both a strength and a vulnerability. Policy decisions that weaken healthcare employment, including Medicaid cuts and Department of Government Efficiency (DOGE) layoffs, do not just affect the health system. They ripple through the entire economy.
HealthTech M&A Surge Hits Record Levels
Deal value in health technology mergers and acquisitions soared 87% to 31.8 billion euros. PE healthcare deals now account for 38% of total transaction value. Deal volumes are forecast to increase 11% year over year in 2026. The Enhabit home health deal at $1.1 billion (approximately 10 times earnings) is setting valuation benchmarks for the home health sector. Capital is concentrating around companies with proven operational models and clear paths to margin improvement.3
Why it matters: The 87% surge in deal value signals that buyers are confident enough to pay premium prices for healthcare technology assets. For operators, this means strategic acquirers are active and valuations are favorable. For builders, the exit environment is the strongest in two years.
CMS ACCESS Model Launches 10-Year Chronic Care Play
Unveiled at ViVE 2026, the Center for Medicare and Medicaid Innovation (CMMI) ACCESS Model is the biggest structural signal for value-based care (VBC) since the Medicare Shared Savings Program (MSSP). This decade-long initiative ties chronic disease management to outcomes-based reimbursement with scalable technology requirements. In a week dominated by institutional fracturing, the ACCESS Model stands as the one constructive federal signal for healthcare delivery transformation.4
Why it matters: A 10-year model removes the uncertainty that killed previous CMMI experiments. Capital can now underwrite chronic care platforms with confidence in the reimbursement timeline. Digital health companies with outcomes measurement built into their platforms just received a decade-long federal runway.
Troughs
FDA in Operational Crisis
The government shutdown halted new drug, biologic, and device submissions at the Food and Drug Administration. Staff are hemorrhaging. Rare disease programs face critical delays. The FDA's Digital Health Center appointed a former health AI executive as leader, signaling a pro-AI regulatory posture, but the agency cannot review what it cannot process. For biotech companies with pending submissions, every day of delay costs money and extends timelines for patients waiting on therapies.5
Why it matters: The FDA is the gatekeeper for every new therapy, device, and diagnostic in the United States. An operational crisis at the agency creates supply chain uncertainty, delays innovation pipelines, and undermines the regulatory stability that capital markets depend on for healthcare investment decisions.
OBBBA Medicaid Cuts Now Quantified
The RAND Corporation released a state-by-state analysis projecting $665 billion in total Medicaid funding reduction through 2034 under the One Big Beautiful Bill Act. MercyOne in Des Moines is already announcing layoffs. Rural and safety-net hospitals are entering crisis planning. An estimated 7.6 million fewer people will have insurance by 2034. Democrats are building 2026 midterm campaigns around hospital layoffs tied to these cuts, shifting healthcare spending from policy debate to electoral politics.6
Why it matters: The political window to reverse these cuts is closing as they become campaign ammunition rather than negotiable policy. Every health system chief financial officer doing five-year planning now has a RAND-validated model showing exactly how much federal revenue is at risk, by state.
Health Insurance Costs Eating Pay Raises
The Federal Reserve Bank of New York published research showing that employers are scaling back wages to absorb rising health insurance costs. The dynamic is straightforward: total compensation budgets are fixed, and insurance premium increases are consuming the share that would otherwise go to wage growth. For healthcare workers already stretched by inflation, this means their real earnings are declining even as nominal pay holds steady.7
Why it matters: This creates a vicious cycle for healthcare workforce retention. Workers see flat or declining real wages, which drives burnout and turnover, which drives overtime and agency costs, which drives insurance premiums higher. Breaking the cycle requires structural changes to benefits design, not incremental adjustments.
Trends
PE Disclosure Era Begins
Massachusetts now requires quarterly disclosure of PE healthcare platform investments, effective January 1, 2026. This is the first state mandate of its kind for healthcare PE transparency. Combined with Illinois's proposed broadening of PE healthcare transaction reporting (HB5000) and Colorado Attorney General authority over healthcare transactions, a multi-state PE oversight framework is emerging. The Enhabit home health deal at approximately 10 times earnings is setting valuation benchmarks that will be visible under these new disclosure requirements.8
Why it matters: PE firms that have operated with minimal public scrutiny in healthcare now face mandatory transparency in their largest markets. Disclosure requirements change deal structures, timelines, and valuations. Expect this trend to spread to at least five more states by year-end.
Home Health as M&A Anchor
The $1.1 billion Enhabit deal at approximately 10 times earnings is setting the valuation benchmark for home health acquisitions. Home healthcare is projected to grow from $580 billion to $954 billion by 2033 at a 7.8% compound annual growth rate. CommonSpirit Health at Home's chief executive described their 2026 strategy in three words: "AI, AI, and AI." Home health is emerging as the low-friction deployment zone for clinical AI because regulatory burden is lighter than acute care and patient preference increasingly favors care at home.9
Why it matters: Home health sits at the intersection of three structural tailwinds: aging demographics, AI deployment opportunity, and consumer preference. The 10x earnings multiple signals that acquirers see durable growth. For health systems, home health capacity is becoming a strategic imperative, not an ancillary service.
AI ROI Era Replaces AI Hype Era
ViVE 2026 marked the transition from AI curiosity to AI accountability. Budget constraints, not enthusiasm, are driving purchasing decisions. Vendors without return on investment (ROI) models are being cut from evaluation cycles. NVIDIA reports 70% of healthcare organizations now use AI in some capacity, but the gap between adoption and validated outcomes is widening. Workforce shortage projections now extend to 2038, making AI not optional but necessary for basic operational continuity.10
Why it matters: The AI conversation has shifted from "should we adopt AI?" to "prove the return." Organizations that cannot demonstrate measurable outcomes from their AI investments will face budget cuts, not expansions. The winners in 2026 will be the ones that ship results, not slide decks.
So What?
For Professionals
Healthcare's role as the economy's job engine just hit its first wall. If you have been assuming job security because "healthcare always hires," that assumption needs updating. The February job losses are a warning signal, not a blip. On the constructive side, the ACCESS Model gives chronic care professionals a 10-year federal runway, and the AI ROI shift means organizations are now hiring for AI implementation skills, not just AI enthusiasm. Understanding how to measure and demonstrate AI outcomes is the skill that will differentiate you in the next hiring cycle.
For Leaders and Operators
Three things require immediate attention. First, the $665 billion OBBBA number is now your Medicaid planning baseline. Map your revenue against RAND's state-by-state projections. Second, the FDA operational crisis means drug and device pipelines are freezing; factor supply chain delays into procurement. Third, the ViVE/HIMSS message is clear: AI vendors without ROI models should be dropped from evaluation. Your board wants results, not pilots. The PE disclosure requirements in Massachusetts create new compliance obligations if your system has PE-backed partnerships or investments.
For Builders and Investors
Three investable categories crystallized this week. Home health at 10x earnings multiples with $580 billion to $954 billion growth trajectory and AI as the operational wedge. The ACCESS Model as a 10-year federal runway for chronic care technology platforms with outcomes measurement built in. And AI governance/validation tools, because every organization deploying AI needs infrastructure to prove it works. The 87% surge in healthtech M&A deal value means the exit environment is strong. Build companies that ship measurable ROI. The market is done paying for potential.
On the Calendar
- HIMSS 2026 — March 3-6, Las Vegas
- HLTH 2026 — October, Las Vegas